Mortality from Multiple Myeloma Within One Year Following Autologous Stem Cell Transplantation: Defining an...

Area of Science:

• Hematology
• Oncology
• Stem Cell Transplantation

Background:

• Autologous stem cell transplantation (ASCT) is a key treatment for multiple myeloma (MM).
• Early mortality (EM) post-ASCT, defined as death within one year, affects approximately 5% of patients.
• EM post-ASCT is often attributed to aggressive underlying disease rather than patient comorbidities.

Purpose of the Study:

• To identify characteristics of ultra-high risk patients experiencing EM post-ASCT.
• To analyze factors associated with early death in newly diagnosed multiple myeloma patients undergoing first-line ASCT.

Main Methods:

• Retrospective review of 962 patients with newly diagnosed MM treated with first-line ASCT.
• Matching of 41 patients who died within 1 year (EM group) with controls based on age, sex, and transplant year.
• Multivariate analysis to identify predictors of EM post-ASCT.

Main Results:

• 4.3% of patients (41/962) experienced EM post-ASCT from MM-related causes.
• Anemia, hypercalcemia, high-risk cytogenetics, and elevated lactate dehydrogenase were significantly associated with EM post-ASCT.
• Most EM patients received novel agents and second-line chemotherapy, but survival post-second-line therapy was poor (2.1 months), often due to rapid relapse.

Conclusions:

• Clinical parameters indicating high disease burden and high-risk cytogenetics are associated with EM post-ASCT.
• Despite advances in relapsed/refractory MM treatment, these ultra-high risk patients have dismal survival.
• Further investigation into the biology of relapse and resistance in MM is crucial for improving outcomes in this population.